Latest News and Press Releases

David V. Smith to join Board of Directors Elizabeth Smith and Richard Lopez, M.D., to join Scientific Advisory Board ALAMEDA, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Acepodia, a clinical-stage...

ALAMEDA, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform...

ALAMEDA, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform...

Interim results from ongoing Phase 1 dose-escalation study demonstrate safety and tolerability of repeat dosing with ACE1702, a novel, off-the-shelf natural killer cell therapy Initial results show...

ALAMEDA, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform...

ACE1702 showed superior in vitro and in vivo potency against HER2-expressing cancers Data support continued development of ACE1702 as a potent, safe, off-the-shelf natural killer (NK) cell therapy...

Preclinical data demonstrate potential of off-the-shelf, NK-like gamma-delta T cells in developing cell therapies for the treatment of cancers ACE1831, an allogeneic cell therapy candidate...

SAN MATEO, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced the appointments...

SAN MATEO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced that Sonny Hsiao,...